UNSPSC 51273927: Dextrose/epinephrine/lidocaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273927 Dextrose/epinephrine/lidocaine is a Commodity code that in recent state and local procurement activity covers emergency medical pharmaceuticals, naloxone (Narcan), drug deactivation systems, and generic multi-source pharmaceuticals distributed through authorized channels. State and local governments buying under this code include county health departments, state health agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida recently solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually through an IFB (IFB60459723LAS), with quarterly deliveries to its community health building and a two-year initial contract term with one-year renewal option. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels, signaling state interest in alternative contracting models for pharmaceutical supply. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) in January 2026 sought manufacturers to supply generic pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, requiring NDC-coded products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with a July 1, 2026 effective date and pricing weighted 75 percent of evaluation.

Recent activity concentrates in Florida, Texas, and Minnesota, with the MMCAP opportunity spanning a multi-state region. Seminole County's naloxone procurement (IFB response due July 26, 2023) requires vendors to include all shipping and delivery costs, maintain workers' compensation and commercial general liability coverage, and comply with E-Verify and federal compliance rules potentially tied to FEMA funding. The MMCAP RFP (proposals due March 26, 2026) imposes strict manufacturing compliance including cGMP certification and Drug Supply Chain Security Act adherence, mandates relationships with at least two of the three authorized wholesalers with chargeback capability, and assesses pricing competitiveness at 75 percent weight alongside administrative fee compliance, EDI capability, and fixed pricing. Vendors pursuing pharmaceutical supply to state and local health programs should expect quarterly or regular delivery schedules, federal and state regulatory compliance requirements, established wholesaler channel relationships, and pricing models ranging from flat-fee to net-price or WAC-minus structures.